Quadrant Capital Group’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-135
Closed -$22.8K 1375
2026
Q1
$22.8K Hold
135
﹤0.01% 1962
2025
Q4
$24.7K Hold
135
﹤0.01% 1925
2025
Q3
$16.4K Buy
+135
New +$15.2K ﹤0.01% 2010
2025
Q2
Sell
-135
Closed -$15.7K 1458
2025
Q1
$15.7K Hold
135
﹤0.01% 2099
2024
Q4
$11.4K Hold
135
﹤0.01% 2083
2024
Q3
$12.1K Hold
135
﹤0.01% 2088
2024
Q2
$10.9K Hold
135
﹤0.01% 2092
2024
Q1
$10.8K Hold
135
﹤0.01% 2077
2023
Q4
$10.7K Sell
135
-29
-18% -$1.94K ﹤0.01% 2041
2023
Q3
$11.5K Buy
164
+24
+17% +$1.79K ﹤0.01% 1938
2023
Q2
$10.1K Buy
140
+5
+4% +$369 ﹤0.01% 1990
2023
Q1
$8.33K Hold
135
﹤0.01% 2099
2022
Q4
$10.4K Hold
135
﹤0.01% 1929
2022
Q3
$6K Hold
135
﹤0.01% 2056
2022
Q2
$5K Buy
135
+70
+108% +$2.21K ﹤0.01% 1937
2022
Q1
$3K Sell
65
-142
-69% -$4.4K ﹤0.01% 2030
2021
Q4
$8K Buy
207
+7
+4% +$258 ﹤0.01% 1707
2021
Q3
$7K Buy
200
+92
+85% +$3.58K ﹤0.01% 1736
2021
Q2
$7K Sell
108
-3
-3% -$180 ﹤0.01% 1709
2021
Q1
$6K Buy
111
+11
+11% +$774 ﹤0.01% 1699
2020
Q4
$8K Hold
100
﹤0.01% 1473
2020
Q3
$7K Buy
+100
New +$7.79K ﹤0.01% 1356

Other funds holding AXSM

Quadrant Capital Group's AXSM Position: Q2 2026 in Review

Quadrant Capital Group sold out of Axsome Therapeutics (AXSM) in Q2 2026, closing a stake of 135 shares — an estimated $22.8K sold.

Quadrant Capital Group first reported a position in AXSM in Q3 2020 and held it in 22 quarters. The position peaked at $24.7K in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Quadrant Capital Group reported no remaining Axsome Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 135 Axsome Therapeutics shares in Q2 2026, an estimated $22.8K.
  • Quadrant Capital Group first reported a position in Axsome Therapeutics in Q3 2020 and held it in 22 quarters.
  • Quadrant Capital Group's Axsome Therapeutics position peaked at $24.7K in Q4 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.